ACM
FATE icon

Anfield Capital Management’s Fate Therapeutics FATE Stock Holding History

Anfield Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,470
Closed -$29K – 196
2019
Q4 		$29K Buy
+1,470
New +$23.3K 0.01% 240

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Anfield Capital Management's FATE Position: Q1 2020 in Review

Anfield Capital Management sold out of Fate Therapeutics (FATE) in Q1 2020, closing a stake of 1,470 shares — an estimated $29K sold.

Anfield Capital Management first reported a position in FATE in Q4 2019 and held it in 1 quarter. The position peaked at $29K in Q4 2019. 156 funds tracked by Wall St. Rank hold FATE as of Q1 2020.

  • Anfield Capital Management reported no remaining Fate Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Anfield Capital Management sold 1,470 Fate Therapeutics shares in Q1 2020, an estimated $29K.
  • Anfield Capital Management first reported a position in Fate Therapeutics in Q4 2019 and held it in 1 quarter.
  • Anfield Capital Management's Fate Therapeutics position peaked at $29K in Q4 2019.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2020.

Based on Anfield Capital Management's 13F filing for Q1 2020, filed 7 May 2020.